GenScript Biotech Corporation announced the GenScript and NVIDIA Life Sciences Startup PitchFest, a global competition for startups applying artificial intelligence to therapeutic discovery and life sciences. The program brings together GenScript's wet lab validation and data generation capabilities and NVIDIA's accelerated computing platforms and startup ecosystem to help selected companies advance AI-driven platforms toward biological proof, investor engagement, and industry visibility.
AI is making therapeutic discovery more expansive than ever, giving scientists new ways to generate hypotheses, identify targets, and design candidates at unprecedented speed. The PitchFest is designed to channel that momentum by connecting emerging AI drug discovery and life science companies with investors, technology leaders, and partners focused on turning computational predictions into biological proof. The competition will feature startups developing technologies such as AI-driven antibody and protein design, as well as technologies that accelerate the design-build-test-learn cycle.
"To harness the true potential of AI in life sciences, we must build an ecosystem where world-class computation meets trusted, scalable biological validation," said Ray Chen, President of GenScript Life Science Group. "Success in this space requires a connected pathway that brings together data, experimental evidence, and investment to help innovators move with confidence from computational promise to therapeutic progress. PitchFest gives digital biology startups integrated support to rapidly test their models, generate evidence, and accelerate breakthrough therapies."